该产品的获批填补了国内QX型鸡传染性支气管炎病毒多联疫苗的市场空白，体现了公司在禽用疫苗领 域的前瞻布局和创新实力，完善了公司禽用疫苗产品线，有助于进一步巩固公司在禽用疫苗领域的头部 地位，并将为公司带来新的业绩增长点。 智通财经APP讯，瑞普生物(300119.SZ)发布公告，根据《兽药管理条例》和《兽药注册办法》的规定， 公司及下属分子公司天津瑞普生物技术股份有限公司空港经济区分公司、瑞普(保定)生物药业有限公 司、广州市华南农大生物药品有限公司近日获得由农业农村部核发的《新兽药注册证书》。新兽药名 称：鸡新城疫、传染性支气管炎、禽流感(H9亚型)、传染性法氏囊病四联灭活疫苗(LaSota株 +RPVA0406株+TJ-4株+RPVA0706株)。 ...

该产品的获批填补了国内QX型鸡传染性支气管炎病毒多联疫苗的市场空白，体现了公司在禽用疫苗领 域的前瞻布局和创新实力，完善了公司禽用疫苗产品线，有助于进一步巩固公司在禽用疫苗领域的头部 地位，并将为公司带来新的业绩增长点。 智通财经APP讯，瑞普生物(300119.SZ)发布公告，根据《兽药管理条例》和《兽药注册办法》的规定， 公司及下属分子公司天津瑞普生物技术股份有限公司空港经济区分公司、瑞普(保定)生物药业有限公 司、广州市华南农大生物药品有限公司近日获得由农业农村部核发的《新兽药注册证书》。新兽药名 称：鸡新城疫、传染性支气管炎、禽流感(H9亚型)、传染性法氏囊病四联灭活疫苗(LaSota株 +RPVA0406株+TJ-4株+RPVA0706株)。 ...

猪塞内卡病毒病是由小核糖核酸病毒科塞内卡病毒属的塞内卡病毒 A(Seneca virus A，SVA)引起的一种 主要感染猪的病毒性传染病。该病主要通过接触传播，可以引起猪的鼻吻、蹄部冠状带水泡病变，与口 蹄疫、猪水泡病和水泡性口炎等疾病在临床上难以区分。该病已在加拿大、巴西和美国等国家流行。 智通财经APP讯，科前生物(688526.SH)发布公告，根据《兽药管理条例》和《兽药注册办法》规定， 经中华人民共和国农业农村部审查，批准公司申报的猪塞内卡病毒病灭活疫苗(HB16 株，悬浮培养)为 新兽药，并核发《新兽药注册证书》。 ...

猪塞内卡病毒病是由小核糖核酸病毒科塞内卡病毒属的塞内卡病毒A(Seneca virus A，SVA)引起的一种 主要感染猪的病毒性传染病。该病主要通过接触传播，可以引起猪的鼻吻、蹄部冠状带水泡病变，与口 蹄疫、猪水泡病和水泡性口炎等疾病在临床上难以区分。该病已在加拿大、巴西和美国等国家流行。 科前生物(688526.SH)发布公告，根据《兽药管理条例》和《兽药注册办法》规定，经中华人民共和国 农业农村部审查，批准公司申报的猪塞内卡病毒病灭活疫苗(HB16株，悬浮培养)为新兽药，并核发 《新兽药注册证书》。 ...

Core Viewpoint - The announcement highlights the approval of a new veterinary drug, specifically an inactivated vaccine for porcine parvovirus, developed by the company's subsidiary and partners, indicating a significant advancement in the veterinary pharmaceutical sector [1]. Group 1 - The company, BioShares, announced the approval of a new veterinary drug by the Ministry of Agriculture and Rural Affairs [1]. - The approved product is an inactivated vaccine for porcine parvovirus, known as rPP03 strain [1]. - The vaccine was developed in collaboration with the company's wholly-owned subsidiary, Yangzhou Youbang Biological Pharmaceutical Co., Ltd., and Jinyu Baoling Biological Pharmaceutical Co., Ltd., among others [1].

Core Viewpoint - The company has received approval from the Ministry of Agriculture and Rural Affairs for its new veterinary drug, "Mirtazapine Ointment," which addresses significant clinical signs in cats such as decreased appetite and weight loss, potentially leading to severe health issues if untreated [1] Group 1: Product Development - The company, along with its subsidiaries, has successfully developed a new veterinary drug classified as a Category V new veterinary drug, which has been officially registered [1] - The new product, Mirtazapine Ointment, is designed to meet clinical needs in the pet market, particularly for cats experiencing appetite loss [1] Group 2: Product Characteristics - The Mirtazapine Ointment is characterized by controllable quality, safety and effectiveness, ease of administration, and high compliance [1] Group 3: Market Context - Currently, the company has not been able to find any information regarding the sales status and market share of similar products in circulation through public channels [1]

Core Viewpoint - The company has received the first clinical trial approval for an mRNA vaccine for economic animals in China, marking a significant milestone in its veterinary mRNA vaccine development platform [1] Group 1: Company Developments - The company, 瑞普生物, announced that it has obtained a clinical trial approval from the Ministry of Agriculture and Rural Affairs for its mRNA vaccine targeting porcine epidemic diarrhea virus (RPS1903) [1] - This approval signifies that the company possesses a mature research and development platform for veterinary mRNA vaccines, which is expected to broaden its product line and development opportunities [1] Group 2: Industry Context - The approval of the mRNA vaccine is a pioneering step in the domestic market for economic animals, indicating a potential shift in veterinary vaccine development [1] - It is important to note that after obtaining clinical trial approval, the vaccine must complete clinical trials and submit for registration, which involves review and approval by the Ministry of Agriculture and Rural Affairs before it can be marketed [1]

Core Viewpoint - The company Shunlian Bio has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its genetically engineered subunit vaccine for swine fever, along with the issuance of the veterinary drug product approval number [1] Group 1 - The approval signifies a significant milestone for the company's product development in the veterinary vaccine sector [1] - The vaccine is expected to enhance the company's market position in the animal health industry [1] - This development may lead to increased revenue opportunities for the company in the future [1]

Group 1 - Multiple companies, including Tangde Film and Television, Rhine Sports, Zhengwei New Materials, and Ruipu Biology, announced name changes to align with their strategic transformations in 2025 [1][2][3] - Tangde Film and Television will change its name to Zhejiang Huazhi Digital Media Co., Ltd. on April 25, 2025, to better reflect its future development direction and enhance brand recognition [1] - Rhine Sports changed its name to Chengdu Xintiandi Cultural Tourism Development Co., Ltd. to better align with its business characteristics and strategic positioning [2] Group 2 - Jinmao Yinniao announced a name change to Mount Everest Gold Group Company Limited, reflecting its focus on the jewelry new retail business, which contributed over 97% of its revenue for the six months ending June 30, 2024 [2][3] - Ruipu Biology changed its name to Ruipu Biological Co., Ltd. to better suit its expanded business scope and enhance its brand image, having established a significant presence with over 20 subsidiaries and 100 new veterinary drug registrations [3] - AVIC Electromechanical changed its name to AVIC Chengfei after completing a major asset restructuring, with Chengfei becoming its wholly-owned subsidiary [3]